Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Overview

About this study

The purpose of this study is to determine if glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Informed consent obtained before any trial-related activity

- Completed the full treatment period of the extension trial EASE SBS 2 (ZP1848-17127)

Exclusion Criteria:

- Any condition, disease, or circumstance that in the Investigator's opinion would put
the patient at any undue risk, prevent completion of the trial, or confound the
planned assessments of the trial

- Not having a colonoscopy performed at End of Trial in EASE SBS 2 (for patients with
remnant colon). Note. The results of the colonoscopy must not give rise to any safety
concerns. A colonoscopy performed within 6 months prior to End of Trial and not giving
rise to any safety concerns is accepted. For patients with a remnant colon, which is
not connected to the passage of foods and is thereby dormant, a computerized
tomography (CT) scan or magnetic resonance imaging (MRI) will suffice at the
discretion of the Investigator

- Use of GLP-1, GLP-2, human growth hormone (HGH), dipeptidyl peptidase-4 (DPP-4)
inhibitors, somatostatin, or analogs thereof within 3 months. Note: Prior use of
glepaglutide trial drug is allowed

- Females of childbearing potential, who are pregnant, breast-feeding, intend to become
pregnant, or are not using highly effective contraceptive methods

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/9/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ryan Hurt, M.D., Ph.D.

Open for enrollment

Contact information:

Karen Evans

(507) 422-2944

Evans.Karen@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20556003

Mayo Clinic Footer